Protein kinase inhibitors

A method of inhibiting a protein kinase, comprising administering to a subject a therapeutically effective amount of a compound of the general formula

• or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein:
• R1 is H or C1-4 alkyl;
• Q is a bond or C1-4 alkyl;
• A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C1-4 alkyl, CH2F, CHF2, CF3, CN, aryl, hetaryl, OCF3, OC1-4 alkyl, OC2-5 alkylNR4R5, O-aryl, O-heteroaryl, CO2R4, CONR4R5, nitro, NR4R5, C1-4 alkylNR4R5, NR6C1-4 alkylNR4R5, NR4COR5, NR6CONR4R5, or NR4SO2R5;
• R4 and R5 are each independently H, C1-4 alkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1-4 alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, and NR7;
• R6 is H or C1-4 alkyl;
• R7 is H, C1-4 alkyl, aryl, hetaryl, C1-4 alkyl aryl, or C1-4 alkyl hetaryl;
• R2 is 0-2 substituents independently selected from halogen, C1-4 alkyl, OH, OC1-4 alkyl, CH2F, CHF2, CF3, OCF3, CN, C1-4 alkylNR8R9, OC1-4 alkylNR8R9, CO2R8, CONR8R9, NR8R9, NR8COR9,NR10CONR8R9, and NR8SO2R9;
• R8 and R9 are each independently H, C1-4 alkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1-4 alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, and NR11;
• R10 is H, C1-4 alkyl, aryl or hetaryl;
• R11 is H, C1-4 alkyl, aryl, hetaryl, C1-4 alkyl aryl, or C1-4 alkyl hetaryl;
• Y is halogen, OH, NR12R13, NR12COR13, NR12CONR13, NR12SO2R13 or NHSO2(phenyl);
• R12 and R13 are each independently H, CH2F, CHF2, CF3, CN, C1-4 alkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-6 membered ring optionally containing an atom selected from O, S, and NR14 and R14 is H or C1-4 alkyl;
• n=0-4;
• W is H, C1-4 alkyl or C2-6 alkenyl where C1-4 alkyl or C2-6 alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, or NR15R16;
• R15 and R16 are each independently H, C1-4 alkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, and NR17 and R17 is H or C1-4 alkyl;
• when Y is OH or NHCOCH3 then R2 is 1-2 substituents;
• and
• when Y is NH2 and R2 is absent then Y is in the para position.